Evidence map›Paper›PMID 40058102›Full record

ArticleThe International journal on drug policy2025

Cannabis legalization and increasing cannabis use in the United States: Data from urine toxicology testing in emergency room patients.

David S Fink, Hillary Samples, Carol A Malte, Mark Olfson, Melanie M Wall, Daniel M Alschuler, Tracy Simpson, Zachary Mannes, Andrew J Saxon, Deborah S Hasin

Abstract read
In one paragraph

Article in The International journal on drug policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

David S FinkNew York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA.
Hillary SamplesRutgers Institute for Health, Healthcare Policy and Aging Research, 112 Paterson St, New Brunswick, NJ 08901, USA.
Carol A MalteHealth Services Research & Development (HSR&D) Seattle Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Puget Sound Health Care System, 1660 S Columbian Way, Seattle, WA 98108, USA; Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System, 1660 S Columbian Way, Seattle, WA 98108, USA.
Mark OlfsonColumbia University Irving Medical Center, 630 West 168th Street, New York, NY 10032, USA.
Melanie M WallNew York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA; Columbia University Irving Medical Center, 630 West 168th Street, New York, NY 10032, USA.
Daniel M AlschulerNew York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA.
Tracy SimpsonHealth Services Research & Development (HSR&D) Seattle Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Puget Sound Health Care System, 1660 S Columbian Way, Seattle, WA 98108, USA; Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System, 1660 S Columbian Way, Seattle, WA 98108, USA; University of Washington School of Medicine, 1959 NE Pacific St, Seattle, WA 98195, USA.
Zachary MannesColumbia University Irving Medical Center, 630 West 168th Street, New York, NY 10032, USA.
Andrew J SaxonHealth Services Research & Development (HSR&D) Seattle Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Puget Sound Health Care System, 1660 S Columbian Way, Seattle, WA 98108, USA; Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System, 1660 S Columbian Way, Seattle, WA 98108, USA; University of Washington School of Medicine, 1959 NE Pacific St, Seattle, WA 98195, USA.
Deborah S HasinNew York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA; Columbia University Irving Medical Center, 630 West 168th Street, New York, NY 10032, USA. Electronic address: deborah.hasin@nyspi.columbia.edu.

Funding

Impact of Medical and Recreational Marijuana Laws On Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 - 2024R01DA048860 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI HASIN, DEBORAH S · 2019 to 2023
$4.1M
COVID-19 Pandemic: Natural Experiment in Telehealth on Buprenorphine Treatment in a Large Integrated Healthcare SystemK99DA055724 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI FINK, DAVID STANLEY · 2023 to 2023
$174k
NIDA NIH HHS K99 DA055724NIDA NIH HHS R01 DA048860
6 · The paper itself

Abstract

STUDY

objectivesRates of cannabis use disorder (CUD) appear to be increasing nationally, with increases greater in states that legalized cannabis use. However, as legalization has progressed and stigma declined, some of these apparent increases could be due to greater willingness of survey respondents and patients to acknowledge cannabis involvement. Biological indicators of cannabis use overcome some concerns about trends denoted by self-report data whose validity is potentially changing over time. Our objective was to investigate the relationship between medical cannabis laws (MCL) and recreational cannabis laws (RCL) and the prevalence of cannabis-positive urine drug screens (UDS) in a large patient sample.

methodsVeterans Health Administration (VHA) emergency department (ED) patients aged 18-75 years with ≥1 ED visit for any reason in a given year from 2008 to 2019 were included. Staggered-adoption difference-in-difference analysis was used to estimate the association between MCL and RCL enactment on cannabis-positive UDS, fitting adjusted linear binomial regression models.

resultsAdjusted cannabis-positive UDS prevalences increased from 16.4 % to 25.6 % in states with no cannabis law, 16.6 % to 27.6 % in MCL-only-enacting states, and 18.2 % to 33.8 % in RCL-enacting states. MCL-only and RCL enactment was associated with a 0.8 % (95 % CI, 0.4-1.0) and 2.9 % (95 % CI, 2.5-3.3) increase in prevalence of cannabis-positive UDS, respectively.

conclusionsMCL and RCL enactment played a significant role in the overall increases in cannabis-positive UDS among ED patients. The increase in a biological measure of cannabis use helps reduce concerns about reporting bias as cannabis becomes increasingly legalized.

Indexed as

Emergency Service, HospitalLegislation, DrugMarijuana AbuseMarijuana UseAdolescentAdultAgedCannabisFemaleHumansMaleMedical MarijuanaMiddle AgedPrevalenceSubstance Abuse DetectionUnited StatesMedical MarijuanaCausal inferenceMedical cannabis lawsNatural experimentRecreational cannabis lawsUrine drug screeningVeteran health

Identifiers

PMID40058102
PMCPMC11967342

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.